PMID- 33511239
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220420
IS  - 2328-8957 (Print)
IS  - 2328-8957 (Electronic)
IS  - 2328-8957 (Linking)
VI  - 8
IP  - 1
DP  - 2021 Jan
TI  - Incidence and Severity of Drug Interactions Before and After Switching 
      Antiretroviral Therapy to Bictegravir/Emtricitabine/Tenofovir Alafenamide in 
      Treatment-Experienced Patients.
PG  - ofaa625
LID - 10.1093/ofid/ofaa625 [doi]
LID - ofaa625
AB  - BACKGROUND: Switching antiretroviral therapy (ART) in people with HIV (PWH) can 
      influence their risk for drug-drug interactions (DDIs). The purpose of this study 
      was to assess changes in the incidence and severity of DDIs among PWH who 
      switched their ART to bictegravir/emtricitabine/tenofovir alafenamide 
      (BIC/FTC/TAF). METHODS: This was a multicenter retrospective cohort study of PWH 
      on ART and at least 1 concomitant medication (CM) who switched to BIC/FTC/TAF 
      between 3/2018 and 6/2019. Using the University of Liverpool's HIV Drug 
      Interaction Database, 2 DDI analyses were performed for each patient. The first 
      assessed patients' preswitch ART regimens with their CM list. The second assessed 
      the same CM list with BIC/FTC/TAF. Each ART-CM combination was given a score of 0 
      (no or potential weak interaction), 1 (potential interaction), or 2 
      (contraindicated interaction). A paired t test analyzed changes in total DDI 
      scores following ART switches, and linear regression examined factors 
      contributing to DDI score reductions. RESULTS: Among 411 patients, 236 (57%) had 
      at least 1 DDI present at baseline. On average, baseline DDI scores (SD) were 1.4 
      (1.8) and decreased by 1 point (95% CI, -1.1 to -0.8) after patients switched to 
      BIC/FTC/TAF (P < .0001). After adjusting for demographics, baseline ART, and CM 
      categories, switching to BIC/FTC/TAF led to significant DDI score reductions in 
      patients receiving CMs for cardiovascular disease, neurologic/psychiatric 
      disorders, chronic pain, inflammation, gastrointestinal/urologic conditions, and 
      conditions requiring hormonal therapy. CONCLUSIONS: Treatment-experienced PWH 
      eligible to switch their ART may experience significant declines in number and 
      severity of DDIs if switched to BIC/FTC/TAF.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of 
      Infectious Diseases Society of America.
FAU - Schafer, Jason J
AU  - Schafer JJ
AD  - Department of Pharmacy Practice, Jefferson College of Pharmacy, Thomas Jefferson 
      University, Philadelphia, Pennsylvania, USA.
FAU - Pandit, Neha S
AU  - Pandit NS
AD  - Department of Pharmacy Practice and Science, University of Maryland Baltimore 
      School of Pharmacy, Baltimore, Maryland, USA.
FAU - Cha, Agnes
AU  - Cha A
AD  - Brooklyn Hospital Center, Brooklyn, New York, USA.
FAU - Huesgen, Emily
AU  - Huesgen E
AD  - Department of Pharmacy Practice, Indiana University Health, Indianapolis, 
      Indianapolis, USA.
FAU - Badowski, Melissa
AU  - Badowski M
AD  - Section of Infectious Diseases Pharmacotherapy, Department of Pharmacy Practice, 
      University of Illinois at Chicago, College of Pharmacy, Chicago, Illinois, USA.
FAU - Sherman, Elizabeth M
AU  - Sherman EM
AD  - Department of Pharmacy Practice, College of Pharmacy, Nova Southeastern 
      University, Fort Lauderdale, Florida, USA.
AD  - Division of Infectious Diseases, Memorial Healthcare System, Hollywood, Florida, 
      USA.
FAU - Cocohoba, Jennifer
AU  - Cocohoba J
AD  - Department of Clinical Pharmacy, University of California San Francisco School of 
      Pharmacy, San Francisco, California, USA.
FAU - Shimada, Ayako
AU  - Shimada A
AD  - Division of Biostatistics, Sidney Kimmel Medical College, Thomas Jefferson 
      University, Philadelphia, Pennsylvania, USA.
FAU - Keith, Scott W
AU  - Keith SW
AD  - Division of Biostatistics, Sidney Kimmel Medical College, Thomas Jefferson 
      University, Philadelphia, Pennsylvania, USA.
LA  - eng
PT  - Journal Article
DEP - 20201218
PL  - United States
TA  - Open Forum Infect Dis
JT  - Open forum infectious diseases
JID - 101637045
PMC - PMC7813207
OTO - NOTNLM
OT  - ART
OT  - HIV
OT  - bictegravir
OT  - drug interactions
OT  - switch
EDAT- 2021/01/30 06:00
MHDA- 2021/01/30 06:01
PMCR- 2020/12/18
CRDT- 2021/01/29 05:57
PHST- 2020/09/01 00:00 [received]
PHST- 2020/12/15 00:00 [accepted]
PHST- 2021/01/29 05:57 [entrez]
PHST- 2021/01/30 06:00 [pubmed]
PHST- 2021/01/30 06:01 [medline]
PHST- 2020/12/18 00:00 [pmc-release]
AID - ofaa625 [pii]
AID - 10.1093/ofid/ofaa625 [doi]
PST - epublish
SO  - Open Forum Infect Dis. 2020 Dec 18;8(1):ofaa625. doi: 10.1093/ofid/ofaa625. 
      eCollection 2021 Jan.